Clinical trials of dendritic cell-derived exosomes showed antitumor immunity in patients with advanced non-small cell lung cancer (NSCLC) through boosting NKp30-dependent NK cell functions [85]. This evidence concerns the gene NCR3 and non-small cell lung carcinoma.